Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Proteína quinasa ATR (ataxia telangiectasia y relacionada con Rad3) para el tratamiento del cáncer

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20161024002
Publicado:
26/01/2017
Caducidad:
09/11/2017
Resumen:
Una universidad alemana ofrece una proteína quinasa ATR (ataxia telangiectasia y relacionada con Rad3) para el tratamiento del cáncer. Esta proteína ha demostrado su eficacia en varios ensayos celulares y una farmacodinámica prometedora. La ATR desempeña una función crucial en el mantenimiento de la integridad del genoma durante la replicación del ADN y está implicada en la coordinación de la respuesta al daño del ADN y en la reparación de las vías de señalización. La universidad busca empresas que desarrollen agentes terapéuticos para establecer acuerdos de licencia, así como para continuar con el desarrollo en el marco de un acuerdo de investigación.

Details

Tittle:
Novel compound targeting ATR (ataxia telangiectasia and Rad3-related) protein kinase for cancer treatment
Summary:
A German university offers an advanced ATR (ataxia telangiectasia and Rad3-related) protein kinase for cancer treatment. It proved to be effective in various cellular assays and shows promising pharmacodynamics.The university offers a license agreement as well as research cooperation to industrial partners.
Description:
The ATR (ATM and Rad3 related) kinase plays a crucial role in maintaining genome integrity during DNA replication and is involved in the coordination of the DNA damage response ("DDR") and repair signaling pathways. Activation of ATR is directly triggered by DNA lesions facilitating DNA repair and thus promotes tumor cell survival. Therapeutic inhibition of ATR can reverse this mechanism and thereby increase tumor cell killing. Preventing ATR signaling from stalled replication forks enhances the formation of DNA damage, especially under conditions of increased replication stress as typically observed in cancer cells. Therefore, ATR inhibitors can potentiate the effect of chemotherapy or radiation, which makes ATR an attractive target for cancer therapy. At present, two ATR inhibitors (VX-970 and AZD6738) have already entered clinical studies. However, with the developmental risks associated with these compounds, there is a huge interest in advanced ATR inhibitors displaying an improved safety-/efficacy-profile.

A German university found advanced ATR antagonists, which have been shown to be effective in various cellular assays (both on its own in Burkitt Lymphoma and in combination with cisplatin). Furthermore, they show a promising ADME- (absorption, distribution, metabolism, and excretion of medication) profile as deducted from predictive ADME modelling in relation to the aforementioned ATR inhibitors.

The university seeks companies that develop therapeutic agents for licensing agreements as well as for further development in the framework of a research cooperation.
Advantages and Innovations:
Compared to current ATR inhibitors the German university developed advanced compounds targeting a key player in cancer cells. Furthermore the invention improves the safety-/efficacy-profile of such treatments.
Stage of Development:
Under development/lab tested
IPs:
Patents granted

Partner sought

Type and Role of Partner Sought:
The university offers a license agreement as well as research cooperation. Relevant companies come from the pharmaceutical and biotech sector and develop therapeutic agents for cancer. The new substance could be in-licensed to a new agent and be further developed.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002002 Biología celular y molecular
06001003 Citología, cancerología, oncología
06002005 Ingeniería genética
06001009 Terapia genética - ADN